TABLE 1. Results of cholesterol assays by participants in the UKEQAS satisfactory, and the test was regarded as a relatively poor discriminator of disease. However, the requirements for this assay will change when it is used as a predictor of risk or to assess the efficacy of different treatments. Table 1 shows the results obtained by participants in the UK External Quality Assessment Scheme (UKEQAS) when they analysed one sample of serum for cholesterol in March 1979 and another in December 1982. On both occasions the between-laboratory coefficient of variation (CV) of results obtained with Liebermann-Burchard and AutoAnalyzer methods was greater than that with enzymic methods, which gave significantly lower mean values. Over the last 10 years, the proportion of UK laboratories using enzymic methods has steadily increased to a present level of more than 95% (Table 2) . It can therefore be inferred that the average plasma cholesterol in the UK will appear to have decreased by about 10% solely because methods of estimation have changed. This makes it difficult to draw any reliable conclusions about the true change in the general population, and illustrates the problem of attempting long-term epidemiological studies.
The authorative reports recently published from the Lipid Research Clinics (LRC) trial I. 2 have confirmed that the risk of coronary heart disease (CHD) increases directly with the plasma cholesterol concentration. This and other well-controlled trials'': 4 have shown that treatment with diet and/or drugs can decrease plasma cholesterol and at the same time reduce the incidence of CHD. The reduction in risk in the individual patient is related to the reduction in plasma cholesterol concentration achieved by treatment. 2 Thus a fall of,lO% in cholesterol level in hypercholesterolaemic patients will, on average, reduce the incidence of CHD by about 20%, and proportionately greater benefits may be achieved by larger decreases in cholesterol concentrations.f It has been estimated that dietary treatment could reduce the average cholesterol concentration in the population by about 6%, with a consequent fall in the incidence of CHD of 10-15%. 6 These developments are likely to stimulate further studies of cholesterol levels in different populations, and to encourage active intervention in hypercholesterolaemic patients, with increased monitoring of individuals. Although the adverse effects of cholesterol are mainly mediated by low-density lipoprotein," the assay of total plasma cholesterol appears to give as much clinically useful information as determination of its subfractions, I. 2 and it is technically easier as well as more accurate and precise. However, treatment which is effective in significantly reducing the risk of CHD will, on average, produce relatively small changes in plasma cholesterol concentration, which will be difficult to detect reliably with some of the analytical methods in current use.
Current analytical performance
In the past, most routine methods for the determination of plasma cholesterol were un- 
Reference values
When an analyte is measured in a patient, the observed result is usually compared with the
New performance requirements
In the past, the acceptable CV for cholesterol assay was usually taken to be 6-8%.K More recently, Statland'' has recommended that the within-laboratory analytical CV should be taken as half the within-person CV (presumably whilst on a stable diet). This would give an analytical CV for cholesterol of 2,65%, whereas others have recommended a target CV of 2·2%H or a CV for reference laboratories of less than 3%. III There is little objective basis for most of these estimates. At present some laboratories can achieve an analytical CV of about 2%, and in the UK the top 20% of laboratories have achieved a standard deviation (SD) of 0·09 mmollL or lessK---equivalent to a CV of 1-2%. Is this sufficiently small to detect clinically significant changes in a patient undergoing treatment? If sequential measurements are made on a patient, one result can be regarded as significantly different (with a 95% probability) from a previous one if the change is at least 2·8 times .the analytical SD. II Thus, if the analytical CV is 2%, a change of 5·6% will be just significant. In clinical terms, a fall in cholesterol level'of 10% is accompanied by a reduction of about 20% in the risk of CHD. Therefore a clinician might regard a fall in plasma cholesterol of 5% (ie, about 0·3 mmollL) in a patient at high risk as beneficial and relatively easy to achieve. It is clear that an analytical CV of 2% (currently attained by perhaps 'only 20% of UK laboratories) maintained over the period of treatment, would be barely adequate to detect these changes. It seems desirable therefore, to aim at achieving a within-laboratory CV of about 1%. reference range obtained from an apparently healthy population in order to decide whether it is 'abnormal'. Recently new age-and sexspecific reference values for cholesterol have been published.F based on studies made by the LRC on 60 502 North Americans. These show that many persons within the conventional 95% reference range (about 3·0-7·5 mmollL) are at risk of CHD. Men with plasma cholesterol levels above the 80th centile accounted for more than half the excess coronary events attributable to hypercholesterolaemia, and patients with cholesterol concentrations above 6·25 mmollL are especially likely to reduce their risk of CHD if they lower their levels.P The risk of fatal CHD increases for every plasma cholesterol increment above 4·5 rnrnol/L." The assessment of an individual patient should therefore not be based on a conventional 95% reference range and, because plasma cholesterol concentration depends on age, sex and diet, there is little point in each laboratory determining its own reference range. III Clinicians are likely to base their actions on data, derived in the studies described above relating cholesterol level to risk, rather than on locally-determined and possibly different reference ranges. It has been suggested that there is an 'optimal' plasma cholesterol level and, although estimates of this vary, the consensus seems to be that in adults it is about 4·5 mrnol/Li'" more than half the population have levels above this figure. Oliver " has suggested that treatment in the individual patient should be initiated when the plasma cholesterol is raised to more than one SD above the population mean (ie, about 6·5 mmollL for the general population). Others!" have recommended slightly lower figures. However, any such action limits can only be an arbitrary guide, and other clinically relevant factors will be taken into account in deciding when to initiate treatment.
Accuracy
In future, clinical practice is likely to be based on recommendations arising from major studies in which cholesterol measurements are made by well-defined methods in scrupulously controlled laboratories. Clearly, major difficulties would occur if measurements differed in accuracy from those used in the LRC Program. However, any such differences will be difficult to assess because there are relatively few reference materials with authenticated accurate cholesterol values which would be acceptable for the verification of accuracy. Methods will need to be standardised, and the choice of an accurate calibration standard can be difficult. III At present many laboratories regard plasma and serum as equally suitable for this assay, III but there is now good evidence that plasma gives results 3% lower than serum throughout the concentration range. 12 Since plasma was used in the definitive studies made by the LRC, the simplest course would be to adopt it universally. Sources of pre-analytical error, such as venous stasis, need to be reduced or eliminated. 17 As a preliminary target, it would seem desirable that the accuracy of plasma cholesterol assays made in different laboratories should not differ by more than 5%. This figure is arbitrary, but differences much greater than this could lead to variations in interpretation and clinical action arising solely from differences in laboratory accuracy.
Conclusions
There is now a case for attempting to decrease plasma cholesterol concentrations in the population as a whole. 'i To detect changes, both in the individual patient and in epidemiological studies of populations, will require measurements which are more accurate and precise than generally achieved at present. In the individual, results will fluctuate because of both analytical and biological variations. Consequently clinicians should repeat the estimation on a second occasion I.l before embarking on treatment with diet or drugs, both of which will have a long-term impact on the lifestyle of the patient. They should also be aware that their local laboratories may consistently give results which are higher or lower than those obtained with the research methods used to establish the values upon which their clinical actions are based. Clinical chemists must improve their methods to minimise these problems. Although the adoption of standard methods has so far been generally resisted in the UK, it must now be seriously considered for the determination of plasma cholesterol concentrations.
